Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence

BACKGROUND: Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006. However, it was unsuccessful in treating certain cancers, particularly metastatic breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Denian, Xiao, Fei, Feng, Zhongxue, Li, Min, Kong, Lingmiao, Huang, Luping, Wei, Yong’gang, Li, Hongyu, Liu, Fei, Zhang, Haili, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526390/
https://www.ncbi.nlm.nih.gov/pubmed/32993785
http://dx.doi.org/10.1186/s13058-020-01346-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526390/
https://www.ncbi.nlm.nih.gov/pubmed/32993785
http://dx.doi.org/10.1186/s13058-020-01346-y

Ejemplares similares